These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22871998)

  • 1. Ammonia-lowering strategies for the treatment of hepatic encephalopathy.
    Rose CF
    Clin Pharmacol Ther; 2012 Sep; 92(3):321-31. PubMed ID: 22871998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
    Wright G; Noiret L; Olde Damink SW; Jalan R
    Liver Int; 2011 Feb; 31(2):163-75. PubMed ID: 20673233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hyperammonemia in liver failure.
    Jover-Cobos M; Khetan V; Jalan R
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To pee or not to pee: ammonia hypothesis of hepatic encephalopathy revisited.
    Mpabanzi L; Olde Damink SW; van de Poll MC; Soeters PB; Jalan R; Dejong CH
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):449-54. PubMed ID: 21537121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.
    Holecek M
    Metab Brain Dis; 2014 Mar; 29(1):9-17. PubMed ID: 23996300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
    Romero Gómez M; Bautista JD; Grande L; Ramos Guerrero RM; Sánchez Muñoz D
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():40-8. PubMed ID: 15195533
    [No Abstract]   [Full Text] [Related]  

  • 8. Direct molecular and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure.
    Chatauret N; Desjardins P; Zwingmann C; Rose C; Rao KV; Butterworth RF
    J Hepatol; 2006 Jun; 44(6):1083-8. PubMed ID: 16530878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy.
    Tapper EB; Jiang ZG; Patwardhan VR
    Mayo Clin Proc; 2015 May; 90(5):646-58. PubMed ID: 25865476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Disturbances in ammonia metabolism in hepatic failure].
    Ytrebø LM
    Tidsskr Nor Laegeforen; 2007 May; 127(11):1514-7. PubMed ID: 17551556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
    Blanco Vela CI; Poo Ramírez JL
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure.
    Ytrebø LM; Sen S; Rose C; Ten Have GA; Davies NA; Hodges S; Nedredal GI; Romero-Gomez M; Williams R; Revhaug A; Jalan R; Deutz NE
    Am J Physiol Gastrointest Liver Physiol; 2006 Sep; 291(3):G373-81. PubMed ID: 16782695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical science workshop: targeting the gut-liver-brain axis.
    Patel VC; White H; Støy S; Bajaj JS; Shawcross DL
    Metab Brain Dis; 2016 Dec; 31(6):1327-1337. PubMed ID: 26446022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hepatic encephalopathy in patients with cirrhosis.
    Wright G; Jalan R
    Best Pract Res Clin Gastroenterol; 2007; 21(1):95-110. PubMed ID: 17223499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy.
    Brusilow SW; Koehler RC; Traystman RJ; Cooper AJ
    Neurotherapeutics; 2010 Oct; 7(4):452-70. PubMed ID: 20880508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamine: a Trojan horse in ammonia neurotoxicity.
    Albrecht J; Norenberg MD
    Hepatology; 2006 Oct; 44(4):788-94. PubMed ID: 17006913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
    Kristiansen RG; Rose CF; Ytrebø LM
    Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for hyperammonemia.
    Hadjihambi A; Khetan V; Jalan R
    Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of brain dysfunction in hyperammonemic syndromes: The many faces of glutamine.
    Butterworth RF
    Mol Genet Metab; 2014; 113(1-2):113-7. PubMed ID: 25034052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.